Rational polytherapy with lacosamide in clinical practice: Results of a Spanish cohort analysis RELACOVA

Epilepsy and Behavior

Volumn 23, Issue 3, 2012, Pages 298-304

  Villanueva, Vicente ^a   López Gomáriz, Elena ^b   López Trigo, Javier ^c   Palau, Juan ^a   García, Manuel ^a   Villarroya, Teresa ^d   Bonet, Macarena ^d   Santafé, Consuelo ^e  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL LLUÍS ALCANYÍS   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^d HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Antiepileptic drug; Lacosamide; Observational study; Partial onset epilepsy; Polytherapy; Refractory epilepsy; Sodium channel blocker

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PREGABALIN; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADOLESCENT; ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; ATAXIA; BLURRED VISION; BODY WEIGHT; CHILD; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIPLOPIA; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; EPILEPSY; ERECTILE DYSFUNCTION; FEMALE; GAIT DISORDER; HUMAN; HYPONATREMIA; HYPOTHYROIDISM; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; PARASOMNIA; PARTIAL ONSET EPILEPSY; PROSPECTIVE STUDY; RHINITIS; SCHOOL CHILD; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT DURATION;

ACETAMIDES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CHI-SQUARE DISTRIBUTION; CHILD; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSERVATION; SODIUM CHANNEL BLOCKERS; SPAIN; TIME FACTORS; YOUNG ADULT;

EID: 84858284935     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2011.11.026     Document Type: Article

References (31)

1. Kwan P., Brodie M.J. Early identification of refractory epilepsy. NEJM 2000, 342:314-319.
2. LaRoche S.M. A new look at the second-generation antiepileptic drugs: a decade of experience. Neurologist 2007, 13:133-139.
3. Errington A.C., Stohr T., Heers C., Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008, 73:157-169.
4. Horstmann R., Bonn R., Cawello W., Doty F., Rudd G.D. Basic clinical pharmacological investigations of the new antiepileptic drug SPM-927 [abstract no. 2.174]. Epilepsia 2002, 43:188.
5. Beyreuther B.K., Freitag J., Heers C., Krebsfanger N., Scharfenecker U., Stohr T. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007, 13:21-42.
6. European Medicines Agency Vimpat: Ficha Técnica O Resumen De Las Características Del Producto 2009, in Spanish, European Medicines Agency, [cited 2011 August 2]; Available from:. http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/000863/WC500050338.pdf.
7. UCB Pharma Limited Vimpat summary of product characteristics. electronic medicines compendium 2011, [cited 2011 July 25]; Available from:. http://www.medicines.org.uk/EMC/printfriendlydocument.aspx?documentid=21158&companyid=133.
8. Ben-Menachem E., Biton V., Jatuzis D., Abou-Khalil B., Doty P., Rudd G.D. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007, 48:1308-1317.
9. Chung S., Sperling M.R., Biton V., et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010, 51:958-967.
10. Halasz P., Kalviainen R., Mazurkiewicz-Beldzinska M., et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009, 50:443-453.
11. Ferrendelli J.A. Relating pharmacology to clinical practice: the pharmacologic basis of rational polypharmacy. Neurology 1995, 45:S12-S16.
12. French J.A., Faught E. Rational polytherapy. Epilepsia 2009, 50(Suppl. 8):63-68.
13. Brodie M.J., Sills G.J. Combining antiepileptic drugs-rational polytherapy?. Seizure 2011, 20:369-375.
14. Sake J.-K., Hebert D., Isojarvi J., et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 2010, 24:1055-1068.
15. Proposal for revised clinical and electroencephalographic classification of epileptic seizures From the Commission on Classification and Terminology of the International League against Epilepsy. Epilepsia 1981, 22:489-501.
16. Gavatha M., Ioannou I., Papavasiliou A.S. Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy. Epilepsy Behav 2011, 20:691-693.
17. Guilhoto L.M., Loddenkemper T., Gooty V.D., et al. Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr Neurol 2011, 44:414-419.
18. Wehner T., Bauer S., Hamer H.M., et al. Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009, 16:423-425.
19. Long-term efficacy of lacosamide for partial-onset seizures: an interim evaluation of completer cohorts exposed to lacosamide for up to 36 months [abstract no. 2.227]. The 63rd Annual Meeting of the American Epilepsy Society; 4-8 Dec 2009; Boston (MA) USA 2009, E. Ben-Menachem, J. French, J. Isojarvi, D. Hebert, P. Doty (Eds.).
20. Long-term efficacy of lacosamide as adjunctive therapy in patients with uncontrolled POS: results from a phase III open-label extension trial [abstract no. 1.263]. The 64th Annual Meeting of the American Epilepsy Society; 3-7 Dec 2010; San Antonio (TX), USA 2010, E. Faught, S. Chung, A. Husain, J. Isojarvi, C. McShea, P. Doty (Eds.).
21. Long-term safety of lacosamide as adjunctive therapy in patients with uncontrolled partial-onset seizures: results from a phase III open-label extension trial [abstract no. 1.265]. The 64th Annual Meeting of the American Epilepsy Society; 3-7 Dec 2010; San Antonio (TX), USA 2010, A. Husain, E. Faught, S. Chung, J. Isojarvi, C. McShea, P. Doty (Eds.).
22. Rosenfeld W., Fountain N.B., Kaubrys G., Heinzen L., McShea C. Lacosamide: an interim evaluation of long-term safety and efficacy as oral adjunctive therapy in subjects with partial-onset seizures [abstract no. 3.191]. Epilepsia 2007, 48:318-319.
23. Kwan P., Arzimanoglou A., Berg A.T., et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51:1069-1077.
24. Costa J., Fareleira F., Ascencao R., Borges M., Sampaio C., Vaz-Carneiro A. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia 2011, 52:1280-1291.
25. Luciano A.L., Shorvon S.D. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007, 62:375-381.
26. Schiller Y., Najjar Y. Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 2008, 70:54-65.
27. Zaccara G., Messori A., Cincotta M., Burchini G. Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies?. Acta Neurol Scand 2006, 114:157-168.
28. Bootsma H.P., Ricker L., Diepman L., et al. Long-term effects of levetiracetam and topiramate in clinical practice: a head-to-head comparison. Seizure 2008, 17:19-26.
29. Chung S., Ben-Menachem E., Sperling M.R., et al. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials. CNS Drugs 2010, 24:1041-1054.
30. Novy J., Patsalos P.N., Sander J.W., Sisodiya S.M. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction?. Epilepsy Behav 2011, 20:20-23.
31. Husain A., Faught E., Chung S., Isojarvi J., McShea C., Doty P. Long-term safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled POS: results from a phase III open-label extension trial. Epilepsia 2011, 52(Suppl. 6):155.